Skip to main content
TipRanks
Go Ultimate75% OFF

Compare Viking Therapeutics (0VQA) vs. Competitors

13 Followers

Comparison Results

Comparison results
NamePriceMarket CapP/E RatioYearly GainAnalyst ConsensusAnalyst Price TargetCompareTop Analysts' Price TargetSmart ScoreFollow
GB:0VQAViking Therapeutics$26.72$3.42B-4.95-27.68%Strong BuyUnlock the GB:0VQA analyst price target with TipRanks PremiumGB:0VQAUnlock the GB:0VQA top-analyst price target with TipRanks Premium
NAMSNewAmsterdam Pharma Company$19.39$2.33B-11.56-49.71%Strong BuyUnlock the NAMS analyst price target with TipRanks PremiumGB:0VQA vs NAMSUnlock the NAMS top-analyst price target with TipRanks Premium
MLYSMineralys Therapeutics, Inc.$14.48$1.29B-3.38-67.28%Strong BuyUnlock the MLYS analyst price target with TipRanks PremiumGB:0VQA vs MLYSUnlock the MLYS top-analyst price target with TipRanks Premium
GPCRStructure Therapeutics, Inc. Sponsored ADR$18.17$1.33B-4.85-51.47%Strong BuyUnlock the GPCR analyst price target with TipRanks PremiumGB:0VQA vs GPCRUnlock the GPCR top-analyst price target with TipRanks Premium
KLRAKailera Therapeutics, Inc.$12.20$1.63B-4.18-53.08%Strong BuyUnlock the KLRA analyst price target with TipRanks PremiumGB:0VQA vs KLRAUnlock the KLRA top-analyst price target with TipRanks Premium
PBLSParabilis Medicines, Inc.$28.25$3.51B-15.17-10.60%Strong BuyUnlock the PBLS analyst price target with TipRanks PremiumGB:0VQA vs PBLSUnlock the PBLS top-analyst price target with TipRanks Premium

Performance Comparison

-100%-50%0%50%100%150%200%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Performance comparison by fund
TickerCompany NamePriceChange% Change
GB:0VQAViking Therapeutics26.72-11.18-29.50%
NAMSNewAmsterdam Pharma Company19.39-19.52-50.17%
MLYSMineralys Therapeutics, Inc.14.48-28.91-66.63%
GPCRStructure Therapeutics, Inc. Sponsored ADR18.17-16.33-47.33%
KLRAKailera Therapeutics, Inc.12.20-13.80-53.08%
PBLSParabilis Medicines, Inc.28.25-3.35-10.60%
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts